gimli
PPLPHARMA stock analysis context
PIRAMAL PHARMA Stock Context for AI Screening
PIRAMAL PHARMA LIMITED is a small-cap stock in Healthcare. This page summarizes key screening signals for PIRAMAL PHARMA, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.
Ask Gimli about PPLPHARMAPrice
₹175.63
1M return
+14.19%
3M return
+9.41%
Market cap
₹23,266.48 cr
PE
-317.80
ROE
-0.91%
RSI
60.53
Turnover
₹25.62 cr
Why it can matter in screens
- Momentum: PPLPHARMA is above 50DMA; RSI is 60.53.
- Returns: 1M +14.19%, 3M +9.41%, 6M -6.77%.
- Liquidity: latest turnover is ₹25.62 cr.
- Valuation: PE -317.80, PB 2.85, ROE -0.91%, ROCE +3.94%.
- Growth: 3Y sales CAGR +11.87%, 3Y profit CAGR -37.64%.
Try these prompts
- Analyze PIRAMAL PHARMA with valuation, momentum and industry peers
- Compare PPLPHARMA with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare PPLPHARMA with other Healthcare stocks
Data snapshot: 2026-05-22. Not investment advice.